These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29420838)

  • 1. Study Design Parameters Affecting Exposure Response Analysis of QT Data: Results From Simulation Studies.
    Ferber G; Sun Y; Darpo B; Garnett C; Liu J
    J Clin Pharmacol; 2018 May; 58(5):674-685. PubMed ID: 29420838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure-response analysis.
    Tsamandouras N; Duvvuri S; Riley S
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):605-616. PubMed ID: 31664592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Bias Evaluation Provide Protection Against False-Negative Results in QT Studies Without a Positive Control Using Exposure-Response Analysis?
    Ferber G; Zhou M; Dota C; Garnett C; Keirns J; Malik M; Stockbridge N; Darpo B
    J Clin Pharmacol; 2017 Jan; 57(1):85-95. PubMed ID: 27271102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.
    Rohatagi S; Carrothers TJ; Kuwabara-Wagg J; Khariton T
    J Clin Pharmacol; 2009 Nov; 49(11):1284-96. PubMed ID: 19734373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Operational Characteristics of Linear Concentration-QT Models for Assessing QTc Interval in the Thorough QT and Phase I Clinical Studies.
    Garnett C; Needleman K; Liu J; Brundage R; Wang Y
    Clin Pharmacol Ther; 2016 Aug; 100(2):170-8. PubMed ID: 26946218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILSI-HESI cardiovascular safety subcommittee dataset: an analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc).
    Chiang AY; Bass AS; Cooper MM; Engwall MJ; Menton RG; Thomas K
    J Pharmacol Toxicol Methods; 2007; 56(2):95-102. PubMed ID: 17588780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
    Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation.
    Piotrovsky V
    AAPS J; 2005 Oct; 7(3):E609-24. PubMed ID: 16353940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?".
    Darpo B; Sarapa N; Garnett C; Benson C; Dota C; Ferber G; Jarugula V; Johannesen L; Keirns J; Krudys K; Ortemann-Renon C; Riley S; Rogers-Subramaniam D; Stockbridge N
    Ann Noninvasive Electrocardiol; 2014 Jan; 19(1):70-81. PubMed ID: 24372708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome.
    Castelletti S; Dagradi F; Goulene K; Danza AI; Baldi E; Stramba-Badiale M; Schwartz PJ
    Int J Cardiol; 2018 Sep; 266():89-94. PubMed ID: 29887480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant.
    Murphy PJ; Yasuda S; Nakai K; Yoshinaga T; Hall N; Zhou M; Aluri J; Rege B; Moline M; Ferry J; Darpo B
    J Clin Pharmacol; 2017 Jan; 57(1):96-104. PubMed ID: 27338807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development.
    Markert M; Shen R; Trautmann T; Guth B
    J Pharmacol Toxicol Methods; 2011; 64(1):25-41. PubMed ID: 21635956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14.
    Darpo B; Garnett C; Keirns J; Stockbridge N
    Drug Saf; 2015 Sep; 38(9):773-80. PubMed ID: 26162419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
    Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
    J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study.
    Shah RR; Maison-Blanche P; Duvauchelle T; Robert P; Denis E
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1451-9. PubMed ID: 26423621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A thorough QT/QTc study of the effect of fasiglifam, a GPR40 agonist, on cardiac repolarization in healthy adults.
    Lee RD; Nudurupati S; Marcinak J; Viswanathan P
    Clin Pharmacol Drug Dev; 2015; 4(3):175-83. PubMed ID: 27140797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.
    Darpo B
    Br J Pharmacol; 2010 Jan; 159(1):49-57. PubMed ID: 19922536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
    Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.